Immunocore (NASDAQ:IMCR – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They currently have a $100.00 target price on the stock. HC Wainwright‘s price objective points to a potential upside of 220.41% from the company’s current price.
A number of other equities research analysts have also issued reports on the stock. Wall Street Zen lowered shares of Immunocore from a “buy” rating to a “hold” rating in a report on Tuesday, July 28th. JPMorgan Chase & Co. assumed coverage on shares of Immunocore in a report on Friday, August 21st. They set an “overweight” rating and a $50.00 price objective for the company. Zacks Research lowered shares of Immunocore from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 3rd. TD Cowen raised shares of Immunocore to a “strong-buy” rating in a report on Monday, August 24th. Finally, Mizuho increased their price objective on shares of Immunocore from $34.00 to $35.00 and gave the company a “neutral” rating in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $56.38.
Immunocore Stock Performance
Shares of NASDAQ:IMCR traded up $0.23 during trading on Monday, hitting $31.21. The company’s stock had a trading volume of 68,557 shares, compared to its average volume of 457,254. The company has a 50-day moving average of $32.82 and a 200-day moving average of $31.66. Immunocore has a 12 month low of $27.50 and a 12 month high of $40.71. The company has a debt-to-equity ratio of 0.94, a current ratio of 4.47 and a quick ratio of 4.44. The firm has a market cap of $1.61 billion, a price-to-earnings ratio of -84.35 and a beta of 0.81.
Immunocore (NASDAQ:IMCR – Get Free Report) last released its earnings results on Friday, August 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.01). Immunocore had a negative return on equity of 4.54% and a negative net margin of 4.20%. On average, sell-side analysts expect that Immunocore will post 0.04 earnings per share for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the business. Engineers Gate Manager LP grew its holdings in shares of Immunocore by 334.3% in the second quarter. Engineers Gate Manager LP now owns 60,327 shares of the company’s stock valued at $1,915,000 after purchasing an additional 46,435 shares in the last quarter. Braidwell LP bought a new stake in Immunocore in the second quarter worth $16,552,000. Eversept Partners LP bought a new stake in Immunocore in the first quarter worth $1,183,000. Public Employees Retirement System of Ohio bought a new stake in Immunocore in the second quarter worth $2,145,000. Finally, Stempoint Capital LP bought a new stake in Immunocore in the first quarter worth $1,916,000. 84.50% of the stock is owned by hedge funds and other institutional investors.
Immunocore Company Profile
Immunocore Holdings plc is a biotechnology company that develops T cell receptor (TCR) therapeutics designed to direct the immune system against cancer and other serious diseases. Its proprietary ImmTAC platform uses engineered TCRs to recognize disease-associated peptides presented on the surface of cells and recruit T cells to attack those cells.
The company’s lead product, KIMMTRAK (tebentafusp-tebn), is an ImmTAC therapy approved in the United States and other markets for the treatment of certain adults with unresectable or metastatic uveal melanoma who have a specific HLA-A*02:01 genotype.
See Also
- Five stocks we like better than Immunocore
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.
